Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term growth hormone responsiveness study in children with idiopathic short stature
NL-OMON24302Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jan 1994
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of somatropin in Idiopathic Short Stature (ISS) (2 arms), sponsored by Pfizer. Primary endpoints: Height at stop of therapy and Final height. Started Jan 1994; status: active, not recruiting.
02
Drugs
somatropin
03
Conditions
Idiopathic Short Stature (ISS)
Beyond the preview
Go deeper on NL-OMON24302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24302.